SCHEMBL6765381

SCHEMBL6765381

N=c1c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2ncn1Cc1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC29A1 Q99808 7/20 0.62
STAT6 P42226 1/20 0.62
ADORA3 P0DMS8 5/20 0.59
TP53 P04637 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
TYMP P19971 1/20 0.58
ADORA1 P30542 3/20 0.57
NFKB1 P19838 2/20 0.57
THPO P40225 2/20 0.57
TSHR P16473 2/20 0.57
ADORA2A P29274 2/20 0.57
LMNA P02545 2/20 0.56
ALDH1A1 P00352 1/20 0.56
GLA P06280 1/20 0.56
PMP22 Q01453 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
NPC1 O15118 1/20 0.56
NPY1R P25929 1/20 0.56
HTT P42858 1/20 0.56
NPY2R P49146 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27732293 0.88 TYMP (0.73) SLC29A1STAT6ADORA3TP53TDP1
SCHEMBL7615673 0.88 TYMP (0.73) SLC29A1STAT6ADORA3TP53TDP1
SCHEMBL5983454 0.88 TYMP (0.73) SLC29A1STAT6ADORA3TP53TDP1
SCHEMBL28310224 0.83 SLC29A1 (0.55) SLC29A1STAT6ADORA3TP53ADORA1
SCHEMBL28660199 0.80 DPP4 (0.54) SLC29A1STAT6ADORA3TP53ADORA1
SCHEMBL23666509 0.79 DPP4 (0.60) SLC29A1STAT6ADORA3TP53ADORA1
SCHEMBL21114408 0.79 DPP4 (0.60) SLC29A1STAT6ADORA3TP53ADORA1
SCHEMBL18512841 0.79 DPP4 (0.60) SLC29A1STAT6ADORA3TP53ADORA1
SCHEMBL19553541 0.79 DPP4 (0.60) SLC29A1STAT6ADORA3TP53ADORA1
SCHEMBL22413038 0.79 ADORA2A (0.58) SLC29A1STAT6ADORA3ADORA1NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110718-A1 Anti-HCV nucleoside derivatives DEVOS RENE (GB) 2004-06-10 US claimed
CN-1466591-A Nucleoside derivatives - 2004-01-07 CN claimed
US-20030008841-A1 Anti-HCV nucleoside derivatives F. HOFFMAN-LA ROCHE, A SWISS COMPANY (CH) 2003-01-09 US claimed
CN-101184495-B Methods, compositions, and formulations for preventing or reducing adverse effects in a patient PERICOR THERAPEUTICS INC 2011-09-14 CN disclosed
CN-101184495-A Methods, compositions, and formulations for preventing or reducing adverse effects in a patient PERICOR THERAPEUTICS INC (US) 2008-05-21 CN disclosed
US-20040110718-A1 Anti-HCV nucleoside derivatives DEVOS RENE (GB) 2004-06-10 US disclosed
CN-1466591-A Nucleoside derivatives - 2004-01-07 CN disclosed
US-20030008841-A1 Anti-HCV nucleoside derivatives F. HOFFMAN-LA ROCHE, A SWISS COMPANY (CH) 2003-01-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030008841-A1 Anti-HCV nucleoside derivatives PNP, HAVCR2, NUDT14 SLC29A1 18/4885STAT6 1423/4885ADORA3 102/4885
US-20040110718-A1 Anti-HCV nucleoside derivatives PNP, HAVCR2, NUDT14 SLC29A1 18/4885STAT6 1423/4885ADORA3 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.